• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coegin Pharma

3.33 SEK-1.19 %10.7, 17.25
Less than 1K followers

COEGIN

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.19 %
-10.00 %
-11.44 %
-22.38 %
-25.00 %
-1.77 %
-61.64 %
-90.58 %
-89.53 %

Coegin Pharma is a Swedish biotechnology company in commercial phase, developing science-based innovations for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
95.21M SEK
Turnover
33.17K SEK
Revenue
79K
EBIT %
-25,888.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
22.7
2026

Extraordinary general meeting '26

19.8
2026

Interim report Q2'26

18.11
2026

Interim report Q3'26

Regulatory press release25.06.2026, 18.46

Notice of extraordinary general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release25.06.2026, 18.45

Coegin Pharma Announces a Directed Issue of Approx. SEK 6.3 Million and Secures Capital Facility Providing Access to SEK 16 Million

Coegin Pharma
Press release16.06.2026, 09.30

Coegin Pharma receives highly encouraging user feedback from Hårklinikken

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release15.06.2026, 09.00

Coegin Pharma enters distribution agreement with LYKO for launch of first VEXIENNE® Follicopeptide® product

Coegin Pharma
Press release02.06.2026, 14.30

Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.

Coegin Pharma
Regulatory press release21.05.2026, 11.00

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release21.05.2026, 09.45

Coegin Pharma AB publishes its interim report for the first quarter of 2026

Coegin Pharma
Press release20.05.2026, 09.30

Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland

Coegin Pharma
Regulatory press release29.04.2026, 14.00

Coegin Pharma AB publishes Annual Report for 2025

Coegin Pharma
Regulatory press release20.04.2026, 09.20

Notice of annual general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Press release16.04.2026, 14.53

Coegin Pharma expands commercial strategy with own-brand distribution model - launches VEXIENNE®

Coegin Pharma
Press release26.03.2026, 14.25

Coegin Pharma's management acquires shares in the company

Coegin Pharma
Press release04.03.2026, 14.30

Coegin Pharma receives first purchase order for new scalp serum

Coegin Pharma
Press release02.03.2026, 11.30

Coegin Pharma accelerates Follicopeptide® portfolio expansion with a new high-performance scalp serum

Coegin Pharma
Regulatory press release26.02.2026, 14.30

Coegin Pharma AB (publ) publishes its year-end report for 2025

Coegin Pharma
Regulatory press release19.02.2026, 18.40

Coegin Pharma carries out directed issues totalling approx. SEK 12.1 million and strengthens the Company's liquidity position

Coegin Pharma
Press release02.01.2026, 09.30

Coegin Pharma provides an operational and strategic update

Coegin Pharma
Press release22.12.2025, 13.30

Coegin Pharma appoints worldleading pigmentation and hair-biology expert Professor Desmond J. Tobin as Scientific Advisor

Coegin Pharma
Press release19.12.2025, 09.25

Coegin Pharma completes first delivery of Follicopeptide products to Hårklinikken

Coegin Pharma
Press release12.12.2025, 11.50

Coegin Pharma delivers first commercial batch of Follicopeptide products to Gents

Coegin Pharma